Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan

Mari Shirotani, Tatsuo Kurokawa, Koji Chiba

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The number of worldwide and Asian multiregional clinical trials (MRCTs) submitted for Japanese New Drug Applications increased markedly between 2009 and 2013, with an increasing number performed for simultaneously submission in the USA, EU, and Japan. Asian studies accounted for 32% of MRCTs (14/44 studies) and had comparatively small sample sizes (<500 subjects). Moreover, the number of Japanese subjects in Asian studies was 2.1- to 13.4-fold larger than the sample size estimated using the method described in Japanese MRCT guidelines, whereas the ratio for worldwide studies was 0.05- to 4.9-fold. Before the introduction of this guidelines, bridging or domestic clinical development strategies were used as the regional development strategy in accordance with ICH E5 guidelines. The results presented herein suggest that Asian studies were conducted when the drug had already been approved in the US/EU, when phase 3 clinical trials were not be planned in the USA/EU, when there was insufficient knowledge of ethnic differences in drug efficacy and safety, or when Caucasian data could not be extrapolated to the Japanese population. New strategies with Asian studies including the Japanese population could be conducted instead of Japanese domestic development strategy.

Original languageEnglish
Pages (from-to)753-764
Number of pages12
JournalJournal of Clinical Pharmacology
Volume54
Issue number7
DOIs
Publication statusPublished - 2014 Jul

Keywords

  • Asian studies
  • globalization of clinical trials
  • multiregional clinical trial
  • regulatory science

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan'. Together they form a unique fingerprint.

  • Cite this